Stock Markets April 28, 2026 01:59 AM

AddLife Q1 Sales Lag Expectations as Currency and Divestments Weigh

Swedish life sciences supplier posts SEK 2.65 billion in Q1 revenue, with margins held steady despite foreign-exchange headwinds

By Derek Hwang
AddLife Q1 Sales Lag Expectations as Currency and Divestments Weigh

AddLife reported first-quarter net sales of SEK 2.65 billion, below the average analyst forecast of SEK 2.74 billion. The company saw a 2% decline in net sales, delivered earnings per share of SEK 1.04, net income of SEK 128 million and EBITA of SEK 332 million. Despite a 4% negative impact from exchange rates, AddLife maintained an EBITA margin of 12.5%, supported by 3% organic growth and 2% growth from acquisitions. The group completed two acquisitions in the UK and Austria during the quarter.

Key Points

  • AddLife reported Q1 net sales of SEK 2.65 billion, missing the average analyst estimate of SEK 2.74 billion and recording a 2% decline in net sales.
  • Profitability metrics remained stable with EPS of SEK 1.04, net income of SEK 128 million and EBITA of SEK 332 million, and an unchanged EBITA margin of 12.5%.
  • Organic expansion of 3% and acquired growth of 2% were offset by divested operations and a 4% negative impact from exchange-rate movements; two acquisitions were completed in the UK and Austria.

AddLife reported first-quarter net sales of SEK 2.65 billion, falling short of the average analyst forecast of SEK 2.74 billion. The company’s reported net sales contracted 2% for the quarter compared with the prior period.

On the profitability side, AddLife recorded earnings per share of SEK 1.04 and reported net income of SEK 128 million. Operating profit before amortization of acquisition-related intangibles - EBITA - was SEK 332 million. The company kept its reported EBITA margin at 12.5% through the quarter.

Management attributed part of the revenue shortfall to adverse currency movements. Exchange-rate effects trimmed both reported sales and EBITA by 4% in the quarter, offsetting some of the underlying growth drivers.

When viewed by growth components, AddLife delivered 3% organic growth and 2% acquired growth. However, those gains were counterbalanced by the sales impact of divested operations and the negative foreign-exchange effects, resulting in the overall decline in reported net sales.

As part of its stated growth strategy, AddLife completed two acquisitions during the quarter, with the new assets located in the United Kingdom and Austria. The acquisitions contributed to the 2% acquired growth recorded for the period.

The quarter therefore combined mixed operational progress - with maintained margins and modest organic expansion - alongside external pressures from currency movements and the accounting effects of divestments. The company’s figures show profitability measures holding steady while reported top-line metrics missed market consensus.

Investors and industry observers will likely note the interplay between underlying growth, recent deal-making activity and the material currency headwinds that subtracted from both sales and EBITA in the quarter.


Financial snapshot

  • Net sales: SEK 2.65 billion (consensus SEK 2.74 billion)
  • Net sales change: -2%
  • Earnings per share: SEK 1.04
  • Net income: SEK 128 million
  • EBITA: SEK 332 million
  • EBITA margin: 12.5%
  • Exchange-rate effect: -4% on sales and EBITA
  • Organic growth: 3%
  • Acquired growth: 2%
  • Acquisitions completed: two (UK and Austria)

Risks

  • Currency fluctuations reduced reported sales and EBITA by 4% in the quarter - a factor that can affect reported performance for companies with cross-border exposure. (Impacted sectors: life sciences suppliers, medical distribution.)
  • Divested operations contributed to the decline in reported sales - divestment effects can mask underlying demand trends and complicate period-on-period comparisons. (Impacted sectors: corporate finance and healthcare supply chains.)
  • Missing the consensus revenue estimate may influence investor sentiment and stock-market reaction in the short term, particularly for stakeholders focused on quarterly beats and misses. (Impacted sectors: equities and investor relations in healthcare supply companies.)

More from Stock Markets

European Markets Retreat as U.S.-Iran Talks Falter and Oil Gains Apr 28, 2026 Oppenheimer Flags Industrial AI Names Focused on Defense and Domestic Manufacturing Apr 28, 2026 European Stocks Slip as US-Iran Negotiations Stall; Earnings Season and Central Bank Meetings Loom Apr 28, 2026 FTSE 100 Opens Lower as Trump Rejects Iran Offer and Hormuz Disruption Keeps Oil Markets Nervous Apr 28, 2026 SIG Group Q1 Tops Forecasts as Margin Gains Offset Softer Demand Apr 28, 2026